Nuvalent (NUVL) Stock Forecast & Price Target

Compare

115 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

NUVL Analyst Ratings

Strong Buy

5 Buy

0 Hold

0 Sell

Based on 5 analysts giving stock ratings to

Nuvalent

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

NUVL Stock 12 Month Forecast

Average Price Target

$111.25

▲(42.19%Upside)

Based on 5 Wall Street analysts offering 12 month price targets for Nuvalent in the last 3 months. The average price target is $111.25 with a high forecast of $125.00 and a low forecast of $100.00. The average price target represents a 42.19% change from the last price of $78.24.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"64":"$64","95":"$95","126":"$126","79.5":"$79.5","110.5":"$110.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":125,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$125.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":111.25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$111.25</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":100,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$100.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[64,79.5,95,110.5,126],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2024","6":"Dec<br/>2024","9":"Mar<br/>2025","12":"Jun<br/>2025","25":"Jun<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,77.18,80.85846153846154,84.53692307692309,88.21538461538462,91.89384615384616,95.5723076923077,99.25076923076924,102.92923076923077,106.6076923076923,110.28615384615385,113.96461538461539,117.64307692307693,121.32153846153847,{"y":125,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,77.18,79.80076923076923,82.42153846153846,85.0423076923077,87.66307692307693,90.28384615384616,92.90461538461538,95.52538461538461,98.14615384615385,100.76692307692308,103.3876923076923,106.00846153846155,108.62923076923076,{"y":111.25,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,77.18,78.93538461538462,80.69076923076923,82.44615384615385,84.20153846153846,85.95692307692308,87.71230769230769,89.46769230769232,91.22307692307693,92.97846153846154,94.73384615384616,96.48923076923077,98.24461538461539,{"y":100,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":65.62,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":75.51,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":76.22,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":85.13,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":103.02,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":89.22,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":94.27,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":78.28,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":85.81,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":74.98,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":68,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":76.23,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":77.18,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$125.00

Average Price Target$111.25

Lowest Price Target$100.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Charles ZhuLifeSci Capital

LifeSci Capital

$110

Buy

40.59%

Upside

Reiterated

06/12/25

Nuvalent's Strong Market Position Bolstered by FDA Approval and Promising Drug Pipeline

Andrew BerensLeerink Partners

Leerink Partners

$125

Buy

59.76%

Upside

Reiterated

06/10/25

Nuvalent's Zidesamtinib: Promising Efficacy and Safety Drive Buy Rating

Peter LawsonBarclays

Barclays

$100

Buy

27.81%

Upside

Reiterated

06/03/25

Analysts Offer Insights on Healthcare Companies: Nuvalent (NASDAQ: NUVL), uniQure (NASDAQ: QURE) and UnitedHealth (NYSE: UNH)

Swayampakula RamakanthH.C. Wainwright

H.C. Wainwright

$110

Buy

40.59%

Upside

Reiterated

05/09/25

Nuvalent's Promising Clinical Developments and Strategic Plans Support Buy Rating

Marc FrahmTD Cowen

TD Cowen

―

Buy

―

Reiterated

05/08/25

Analysts Are Bullish on Top Healthcare Stocks: Nuvalent (NUVL), Prime Medicine, Inc. (PRME)

David DaiUBS

UBS

$100

Buy

27.81%

Upside

Upgraded

03/13/25

Nuvalent upgraded to Buy from Neutral at UBSNuvalent upgraded to Buy from Neutral at UBS

Bradley CaninoStifel Nicolaus

Stifel Nicolaus

$132

Buy

68.71%

Upside

Reiterated

02/28/25

Stifel Nicolaus Keeps Their Buy Rating on Nuvalent (NUVL)

Anupam RamaJ.P. Morgan

J.P. Morgan

$121→$110

Buy

40.59%

Upside

Reiterated

02/28/25

Nuvalent (NUVL) PT Lowered to $110 at JPMorganJPMorgan analyst Anupam Rama lowered the price target on Nuvalent (NASDAQ: NUVL) to $110.00 (from $121.00) while maintaining a Overweight rating.

David NierengartenWedbush

Wedbush

$115

Buy

46.98%

Upside

Reiterated

02/27/25

Christopher RaymondPiper Sandler

Piper Sandler

$102

Buy

30.37%

Upside

Assigned

01/14/25

Piper Sandler Sticks to Their Buy Rating for Nuvalent (NUVL)

Roger SongJefferies

Jefferies

$137

Buy

75.10%

Upside

Reiterated

12/20/24

Nuvalent (NUVL) Receives a Buy from Jefferies

Kelsey GoodwinGuggenheim

Guggenheim

$99→$105

Buy

34.20%

Upside

Reiterated

09/16/24

Nuvalent price target raised to $105 from $99 at GuggenheimNuvalent price target raised to $105 from $99 at Guggenheim

Richard Law CFAGoldman Sachs

Goldman Sachs

―

Sell

―

Reiterated

09/13/24

Goldman Sachs Remains a Sell on Nuvalent (NUVL)

Colleen M. KusyRobert W. Baird

Robert W. Baird

$105

Buy

34.20%

Upside

Reiterated

09/09/24

Baird reiterates Outperform Rating on Nuvalent (NUVL)Baird analyst Colleen Kusy reiterated an Outperform rating and $105.00 price target on Nuvalent (NASDAQ: NUVL).

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Charles ZhuLifeSci Capital

LifeSci Capital

$110

Buy

40.59%

Upside

Reiterated

06/12/25

Nuvalent's Strong Market Position Bolstered by FDA Approval and Promising Drug Pipeline

Andrew BerensLeerink Partners

Leerink Partners

$125

Buy

59.76%

Upside

Reiterated

06/10/25

Nuvalent's Zidesamtinib: Promising Efficacy and Safety Drive Buy Rating

Peter LawsonBarclays

Barclays

$100

Buy

27.81%

Upside

Reiterated

06/03/25

Analysts Offer Insights on Healthcare Companies: Nuvalent (NASDAQ: NUVL), uniQure (NASDAQ: QURE) and UnitedHealth (NYSE: UNH)

Swayampakula RamakanthH.C. Wainwright

H.C. Wainwright

$110

Buy

40.59%

Upside

Reiterated

05/09/25

Nuvalent's Promising Clinical Developments and Strategic Plans Support Buy Rating

Marc FrahmTD Cowen

TD Cowen

―

Buy

―

Reiterated

05/08/25

Analysts Are Bullish on Top Healthcare Stocks: Nuvalent (NUVL), Prime Medicine, Inc. (PRME)

David DaiUBS

UBS

$100

Buy

27.81%

Upside

Upgraded

03/13/25

Nuvalent upgraded to Buy from Neutral at UBSNuvalent upgraded to Buy from Neutral at UBS

Bradley CaninoStifel Nicolaus

Stifel Nicolaus

$132

Buy

68.71%

Upside

Reiterated

02/28/25

Stifel Nicolaus Keeps Their Buy Rating on Nuvalent (NUVL)

Anupam RamaJ.P. Morgan

J.P. Morgan

$121→$110

Buy

40.59%

Upside

Reiterated

02/28/25

Nuvalent (NUVL) PT Lowered to $110 at JPMorganJPMorgan analyst Anupam Rama lowered the price target on Nuvalent (NASDAQ: NUVL) to $110.00 (from $121.00) while maintaining a Overweight rating.

David NierengartenWedbush

Wedbush

$115

Buy

46.98%

Upside

Reiterated

02/27/25

Christopher RaymondPiper Sandler

Piper Sandler

$102

Buy

30.37%

Upside

Assigned

01/14/25

Piper Sandler Sticks to Their Buy Rating for Nuvalent (NUVL)

Roger SongJefferies

Jefferies

$137

Buy

75.10%

Upside

Reiterated

12/20/24

Nuvalent (NUVL) Receives a Buy from Jefferies

Kelsey GoodwinGuggenheim

Guggenheim

$99→$105

Buy

34.20%

Upside

Reiterated

09/16/24

Nuvalent price target raised to $105 from $99 at GuggenheimNuvalent price target raised to $105 from $99 at Guggenheim

Richard Law CFAGoldman Sachs

Goldman Sachs

―

Sell

―

Reiterated

09/13/24

Goldman Sachs Remains a Sell on Nuvalent (NUVL)

Colleen M. KusyRobert W. Baird

Robert W. Baird

$105

Buy

34.20%

Upside

Reiterated

09/09/24

Baird reiterates Outperform Rating on Nuvalent (NUVL)Baird analyst Colleen Kusy reiterated an Outperform rating and $105.00 price target on Nuvalent (NASDAQ: NUVL).

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Nuvalent

1 Month

xxx

Success Rate

6/9 ratings generated profit

Average Return

+2.04%

assigned a xxx

rating 5 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 66.67% of your transactions generating a profit, with an average return of +2.04% per trade.

3 Months

xxx

Success Rate

6/9 ratings generated profit

Average Return

+4.03%

reiterated a xxx

rating 5 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 66.67% of your transactions generating a profit, with an average return of +4.03% per trade.

1 Year

Charles ZhuLifeSci Capital

Success Rate

7/9 ratings generated profit

Average Return

+11.11%

reiterated a buy rating 5 days ago

Copying Charles Zhu's trades and holding each position for 1 Year would result in 77.78% of your transactions generating a profit, with an average return of +11.11% per trade.

2 Years

xxx

Success Rate

7/9 ratings generated profit

Average Return

+39.38%

assigned a xxx

rating 5 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 77.78% of your transactions generating a profit, with an average return of +39.38% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

NUVL Analyst Recommendation Trends

Rating

Feb 25

Mar 25

Apr 25

May 25

Jun 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, NUVL has received 9 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. NUVL average Analyst price target in the past 3 months is 111.25.

Each month's total comprises the sum of three months' worth of ratings.

NUVL Financial Forecast

NUVL Earnings Forecast

Next quarter’s earnings estimate for NUVL is -$1.23 with a range of -$1.38 to -$1.08. The previous quarter’s EPS was -$1.18. NUVL beat its EPS estimate 25.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.03% of the time in the same period. In the last calendar year NUVL has Outperformed its overall industry.

No data currently available

NUVL Sales Forecast

Next quarter’s sales forecast for NUVL is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. NUVL beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.56% of the time in the same period. In the last calendar year NUVL has Preformed in-line its overall industry.

NUVL Stock Forecast FAQ

What is NUVL’s average 12-month price target, according to analysts?

Based on analyst ratings, Nuvalent’s 12-month average price target is 111.25.

What is NUVL’s upside potential, based on the analysts’ average price target?

Nuvalent has 42.19% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is NUVL a Buy, Sell or Hold?

Nuvalent has a consensus rating of Strong Buy which is based on 5 buy ratings, 0 hold ratings and 0 sell ratings.

What is Nuvalent’s price target?

The average price target for Nuvalent is 111.25. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $125.00 ,the lowest forecast is $100.00. The average price target represents 42.19% Increase from the current price of $78.24.

What do analysts say about Nuvalent?

Nuvalent’s analyst rating consensus is a Strong Buy. This is based on the ratings of 5 Wall Streets Analysts.

How can I buy shares of NUVL?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Nuvalent (NUVL) Stock Forecast & Price Target

NUVL Analyst Ratings

NUVL Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Nuvalent

NUVL Analyst Recommendation Trends

NUVL Financial Forecast

NUVL Earnings Forecast

NUVL Sales Forecast

NUVL Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts